Ligand Pharmaceuticals’ Earnings Call Signals Scaled Royalty Push

Ligand Pharmaceuticals Inc ((LGND)) has held its Q1 earnings call. Read on for the main highlights of the call.

Ligand Pharmaceuticals delivered an upbeat earnings call that balanced robust current performance with an ambitious expansion plan. Management highlighted strong royalty growth, rising adjusted profits and a sizable cash war chest, while openly acknowledging GAAP volatility and deal-closing risks. Overall tone leaned confident, with leadership arguing that diversified royalties and the pending XOMA acquisition should outweigh near-term noise.

Royalty Revenue Acceleration

Royalty revenue surged to $43.0 million in the first quarter of 2026, marking a 56% year-on-year increase and underscoring the strength of Ligand’s asset-light model. The growth was driven mainly by contributions from kidney drug Filspari, respiratory therapy Ohtuvayre and oncology product Qarziba, signaling broad-based momentum rather than reliance on a single product.

Total Revenue and EPS Growth

Total revenue climbed 14% year-over-year to $52.0 million, while adjusted diluted EPS rose 23% to $1.63, reflecting expanding profitability from the royalty base. Management stressed that these gains came despite softer Captisol sales and lumpy contract revenue, highlighting the resilience of the underlying recurring revenue stream.

XOMA Royalty Acquisition — Scale and Accretion

Ligand’s pending acquisition of XOMA Royalty, expected to close in the third quarter of 2026, was framed as a transformative deal that will materially scale the portfolio. The transaction will add more than 120 assets, including seven marketed products, nearly double Phase II and III programs, and is projected to be immediately accretive, boosting adjusted EPS by about $0.50 in 2026 and $1.50 in 2027.

Major Clinical and Regulatory Catalysts

Management spotlighted important clinical and regulatory wins, led by Palvella’s QTORIN rapamycin, which delivered positive Phase III SELVA results and beat expectations on its primary endpoint. Travere’s Filspari secured full FDA approval for FSGS, expanding its label and creating a larger commercial runway that should enhance future royalties for Ligand.

Large Peak Opportunity Signals

Ligand underscored the long-term potential of its key partnered drugs by sharing peak sales estimates that could translate into substantial royalty streams. For Filspari, peak sales across IgAN and FSGS are estimated around $3.0 billion, implying roughly $270 million in annual royalties if achieved, while QTORIN rapamycin’s U.S. peak sales are pegged at $1.0–$3.0 billion, translating to a possible $100–$300 million royalty stream.

Improved Operating Efficiency and Scale

Since pivoting to a royalty aggregation strategy, Ligand has aggressively streamlined operations, shrinking its workforce from about 200 employees to around 40 and cutting operating expenses from roughly $90 million to $40 million. At the same time, the company has expanded its deal team and boosted its portfolio of commercial assets from seven to 15, closing 18 transactions over the past three years.

Strong Liquidity Position

The balance sheet emerged as a key pillar of the growth story, with approximately $780 million in cash and investments at quarter end and an undrawn $200 million revolver. This nearly $1.0 billion of available capital gives Ligand flexibility to fund the XOMA transaction and continue pursuing new royalty deals without stretching its financial position.

Multi-year Guidance and Cash Flow Outlook

Looking ahead, management guided 2026 total revenue to a range of $270–$310 million and royalty revenue to $225–$250 million, assuming the XOMA deal closes in the third quarter. Adjusted EPS is projected between $8.50 and $9.50, with operating cash flow expected to reach about $300 million in 2027 and $150–$250 million earmarked annually for reinvestment in new royalty opportunities.

Fair Value Volatility and Nonoperating Expense

Investors were reminded that Ligand’s GAAP results remain subject to swings in the fair value of equity holdings, which can overshadow underlying performance. Nonoperating expense climbed to $41.6 million in the quarter from $14.0 million a year earlier, driven largely by mark-to-market changes in holdings such as Pelthos and contributing to notable earnings volatility.

GAAP Loss Despite Adjusted Profitability

Despite strong adjusted metrics, Ligand still posted a GAAP diluted loss per share of $0.67 in the first quarter, albeit an improvement from a loss of $2.21 in the prior-year period. Management emphasized that non-cash items and fair value adjustments mask the strength of the core royalty business, urging investors to focus on cash generation and adjusted earnings trends.

Captisol and Contract Revenue Lumpiness

The company cautioned that certain revenue streams remain inherently uneven, with Captisol sales down year-on-year in the quarter and expected to remain lumpy. Ligand reiterated its full-year Captisol guidance of $35–$40 million and noted that contract revenue will continue to depend on the timing of partner milestones, creating quarterly variability even as full-year targets stay intact.

Dependence on Partner Execution and Timing Risks

Management acknowledged that many revenue drivers hinge on how effectively partners execute launches, secure reimbursement and achieve regional approvals, which can shift revenue timing. They cited modest headwinds in Ohtuvayre from seasonality and reimbursement delays and noted that Filspari’s approval date slipped into April, underscoring the timing risk built into the model.

Pending Transaction and Uncertain Upside

The XOMA acquisition itself remains a source of both opportunity and uncertainty, as the deal is still pending and key elements like tax attributes are not yet fully quantified. Ligand also highlighted a litigation-linked CVR that offers potential upside without funding obligations, while conceding that the magnitude and usability of XOMA’s tax benefits will only be confirmed after the transaction closes.

Forward-Looking Guidance and Strategic Outlook

Forward-looking guidance reinforced management’s conviction that the royalty aggregation model can deliver sustained growth and rising cash flows. With a robust pipeline of partnered assets, the expected accretion from XOMA and a plan to reinvest hundreds of millions annually into new royalties, Ligand is positioning itself as a diversified, capital-light growth platform, albeit one that requires investors to tolerate GAAP volatility and deal-closing risk.

Ligand’s latest earnings call painted a picture of a company leaning into its strengths as a royalty aggregator while carefully managing the inevitable noise in GAAP results and deal execution. Strong royalty growth, rising adjusted profits, a fortified balance sheet and the pending XOMA acquisition form the core of the bull case, while timing uncertainty and fair-value swings are the main watchpoints for investors tracking the story.